Drug
DS 8201a
DS 8201a: highest development phase Phase 1, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| DS-8201a (DP1) NCT02564900 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow DS 8201a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.